--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
defined in the prospectus dated June 20, 2025 (the “Prospectus ”) issued by Medtide Inc. ( इᅃᔼᖹ (एϪ)ʮ
̡) (the “Company ”).
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an
offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a
prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global
Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in
relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
(including its territories and possessions, any state of the United States and the District of Columbia). This
announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase
or subscribe for any securities in the United States. The Offer Shares have not been, and will not be, registered under
the United States Securities Act of 1933, as amended (the “U.S. Securities Act ”) or securities law of any state or
other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United
States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the U.S. Securities Act. The Offer Shares are being offered and sold solely outside the United States in offshore
transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer
Shares in the United States.
In connection with the Global Offering, Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited act
as the Joint Sponsors; and Morgan Stanley Asia Limited and CLSA Limited act as the Sponsor-Overall Coordinators
and Overall Coordinators.
Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of
the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting
Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting
– Hong Kong Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination ” in the Prospectus
at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday,
June 30, 2025).


--- page 2 ---
2
Medtide Inc.
इᅃᔼᖹ ( एϪ )ʮ̡
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under
the Global Offering
: 16,800,000 H Shares
Number of Hong Kong Offer Shares : 8,400,000 H Shares (as adjusted after
reallocation)
Number of International Offer Shares : 8,400,000 H Shares (as adjusted after
reallocation)
Offer Price : HK$30.60 per H Share, plus brokerage
 of 1.0%, SFC transaction levy
 of 0.0027%, AFRC transaction levy
 of 0.00015% and Hong Kong Stock
 Exchange trading fee of 0.00565%
 (payable in full on application
 in Hong Kong dollars and subject
 to refund)
Nominal value : RMB1.00 per H Share
Stock code : 3880
Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers
Joint Bookrunners and Joint Lead Managers
(in alphabetical order)


--- page 3 ---
3
MEDTIDE INC./ इᅃᔼᖹ (एϪ)ʮ̡
ANNOUNCEMENT OF FINAL OFFER PRICE AND
ALLOTMENT RESULTS
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same
meanings as those defined in the prospectus dated June 20, 2025 (the “Prospectus ”) issued by
Medtide Inc. ( इᅃᔼᖹ (एϪ)ʮ̡ ) (the “Company ”).
Warning: In view of high concentration of shareholding in a small number of Shareholders,
Shareholders and prospective investors should be aware that the price of the H Shares
could move substantially even with a small number of H Shares traded and should exercise
extreme caution when dealing in the H Shares.
SUMMARY
Company information
Stock code 3880
Stock short name MEDTIDE
Dealings commencement date June 30, 2025*
* see note at the end of the announcement
Price Information
Final Offer Price HK$30.60
Offer Price Range HK$28.40 – HK$30.60
Offer Shares and Share Capital
Number of Offer Shares 16,800,000 H Shares
Number of Offer Shares in Hong Kong Public Offering
 (as adjusted after reallocation)
8,400,000 H Shares
Number of Offer Shares in International Offering
 (as adjusted after reallocation)
8,400,000 H Shares
Number of issued Shares upon Listing 141,800,000 Shares
Proceeds
Gross proceeds (Note) HK$514.08 million
Less: Estimated listing expenses payable based on
Final Offer Price
HK$ (85.31) million
Net proceeds HK$428.77 million
Note: Gross proceeds refers to the amount to which the issuer is entitled to receive. For details of the use of
proceeds, please refer to the section headed “Future Plans and Use of Proceeds ” of the Prospectus.


--- page 4 ---
4
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 70,338
No. of successful applications 38,685
Subscription level 301.15 times
Claw-back triggered Yes
No. of Offer Shares initially available under the Hong Kong
Public Offering
1,680,000
No. of Offer Shares reallocated from the International Offering 6,720,000
Final no. of Offer Shares under the Hong Kong Public Offering 8,400,000
% of final no. of Offer Shares under the Hong Kong Public
Offering to the Global Offering
50%
Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can
refer to www.eipo.com.hk/eIPOAllotment  to perform a search by identification number or
www.eipo.com.hk/eIPOAllotment  for the full list of allottees.
INTERNATIONAL OFFERING
No. of placees 115
Subscription Level 2.43 times
No. of Offer Shares initially available under the International
Offering
15,120,000
No. of Offer Shares reallocated to the Hong Kong Public
Offering
6,720,000
Final no. of Offer Shares under the International Offering 8,400,000
% of final no. of Offer Shares under the International Offering
to the Global Offering
50%


--- page 5 ---
5
The Directors confirm that, to the best of their knowledge, information and belief, save for
a written consent under paragraph 5(2) of Appendix F1 to the Listing Rules (the “Placing
Guidelines ”) granted by the Stock Exchange to permit the Company to allocate certain Offer
Shares in the International Offering to a close associate of its existing shareholder 1, (i) none
of the Offer Shares subscribed by the placees and the public have been financed directly or
indirectly by the Company, any of the Directors, the Supervisors, chief executive of the Company,
Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any
of its subsidiaries or their respective close associates; and (ii) none of the placees and the public
who have purchased the Offer Shares are accustomed to taking instructions from the Company,
any of the Directors, the Supervisors, chief executive of the Company, Controlling Shareholders,
substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their
respective close associates in relation to the acquisition, disposal, voting or other disposition of
Shares registered in his/her/its name or otherwise held by him/her/it.
The placees in the International Offering include the following:
Cornerstone Investors
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
% of total
issued
Shares after
the Global
Offering
Existing
shareholders
or their close
associates
Dragon Merit Holdings Limited 1,282,500 7.63% 0.90% No
Welight Capital L.P. 1,282,500 7.63% 0.90% No
Total 2,565,000 15.27% 1.81%
Note:  For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors ” in
the Prospectus.
1 For details, please see “Others/Additional information ” in this announcement


--- page 6 ---
6
Allotee with Consent Obtained
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
% of total
issued
Shares after
the Global
Offering Relationship
Allotee with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Offer
Shares by a close associate of an existing Shareholder
Jingui Yueke (Guangzhou)
Private Equity Investment Limited
Partnership (߅( ᄿψ)ӷ෍
ΥྫΆุ (Υ
ྫ) (“Jingui Yueke ”)
3,346,300 19.92% 2.36% Jingui Yueke is a
close associate of an
existing shareholder
of the Company. Note 1
Notes:
1. The Company has applied for, and the Stock Exchange has granted, a written consent under Paragraph 5(2) of
the Placing Guidelines in relation to allocation to Jingui Yueke, a close associate of an existing shareholder and
pre-IPO investor of the Company, Hangzhou Heda New Pharmaceutical Venture Capital Partnership (Limited
Partnership) (ψձ༺อᔼᖹ௴ุҳ༟ΥྫΆุ (Υྫ )) ( “Hangzhou Heda Xinyiyao ”) to permit
the Company to allocate such Offer Shares in the International Offering to Jingui Yueke. The allocation of
Offer Shares to Jingui Yueke is in compliance with all the conditions under the consent granted by the Stock
Exchange. For details, please refer to the section headed “Others / Additional Information ” in this announcement
below.
2. For details, please refer to the section headed “Others / Additional Information ” in this announcement below.


--- page 7 ---
7
LOCK-UP UNDERTAKINGS
Controlling Shareholders
Name
Number of Shares
held in the Company
subject to lock-up
undertakings
upon Listing
% of total
issued H Shares
after the Global
Offering subject
to lock-up
undertakings
upon Listing
% of
shareholding
in the Company
subject to
lock-up
undertakings
upon Listing
Last day subject
to the lock-up
undertakings Note 1
Qikang International  Notes 1, 2 59,567,875 (including
11,913,575 H Shares)
16.19% 42.01% June 29, 2026  Note 3
Hangzhou Haiding Notes 1, 2 15,410,125 – 10.87% June 29, 2026  Note 3
Ms. Li  Notes 1, 2 10,273,375 (including
5,136,688 H Shares)
6.98% 7.24% June 29, 2026  Note 3
Hangzhou Xiyong  Notes 1, 2 5,136,750 (including
5,136,750 H Shares)
6.98% 3.62% June 29, 2026  Note 3
Hangzhou Yuanxi  Notes 1, 2 5,136,750 (including
5,136,750 H Shares)
6.98% 3.62% June 29, 2026  Note 3
Total 95,524,875 37.13% 67.37%
Notes:
1. Immediately before completion of the Global Offering, Dr. Xu (through Qikang International, an entity
controlled by Dr. Xu through her wholly-owned subsidiary Healthy Angel) and Ms. Li (directly and through
Hangzhou Haiding, an entity controlled by Ms. Li as to 99% and her spouse, Mr. Li Congyan, as to 1%; and
Hangzhou Xiyong and Hangzhou Yuanxi, being partnerships of which Ms. Li is the sole general partner) owned
47.65% and 28.77% of the issued share capital of the Company, respectively, and since the establishment of
the Company, Dr. Xu and Ms. Li have been acting in concert with each other and have agreed to continue
to act in concert with each other after the Listing, provided that they remain key members in the Group or
they remain interested in the share capital of our Company (the “Concert Party Arrangement ”), together
they are collectively entitled to exercise control of approximately 76.42% voting powers of the Company.
Immediately following the completion of the Global Offering, Dr. Xu (through Qikang International, an entity
controlled by Dr. Xu through her wholly-owned subsidiary Healthy Angel) and Ms. Li (directly and through
Hangzhou Haiding, an entity controlled by Ms. Li as to 99% and her spouse, Mr. Li Congyan, as to 1%; and
Hangzhou Xiyong and Hangzhou Yuanxi, being partnerships of which Ms. Li is the sole general partner) will
hold approximately 67.37% of the enlarged issued share capital of the Company. Accordingly, Dr. Xu, Ms. Li,
Qikang International, Healthy Angel, Mr. Li Congyan, Hangzhou Haiding, Hangzhou Xiyong and Hangzhou
Yuanxi are a group of Controlling Shareholders and each of them is subject to the same lock-up as disclosed
above.
2. In view of the Concert Party Arrangement, each of Dr. Xu and Ms. Li is deemed to be interested in the interest
of each other under the SFO.
3. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws. In
accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing Shareholders
ends on June 29, 2026, being 12 months following the Listing Date.


--- page 8 ---
8
Cornerstone Investors
Name
Number of
H Shares held
in the Company
subject to
lock-up
undertakings
upon Listing
% of total
issued H Shares
after the Global
Offering subject
to lock-up
undertakings
upon Listing
% of
shareholding
in the
Company
subject to
lock-up
undertakings
upon Listing
Last day subject
to the lock-up
undertakings Note 1
Dragon Merit Holdings
Limited
1,282,500 1.74% 0.90% December 29, 2025
Welight Capital L.P. 1,282,500 1.74% 0.90% December 29, 2025
Total 2,565,000 3.49% 1.81%
Notes:
1. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December
29, 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares
subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.
Pre-IPO Investors (as defined in the “History, Development and Corporate Structure ” section
of the Prospectus)
Name
Number of
shares held in the
Company subject to
lock-up undertakings
upon listing
% of total
issued H Shares
after the Global
Offering subject
to lock-up
undertakings
upon Listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings Note 1
Lanxi Puhua Shuoyang
Xiaxing Venture
Investment Partnership
(Limited Partnership)
(௴ุҳ
༟ΥྫΆุ (Υྫ ))
9,131,875 (including
9,131,875 H Shares)
12.41% 6.44% June 29, 2026
Quzhou Haibang Taida
Venture Capital Partnership
(Limited Partnership)
(ᜪψऎԞ㹻༺௴ุҳ༟Υ
ྫΆุ(Υྫ ))
7,209,375 (including
7,209,375 H Shares)
9.80% 5.08% June 29, 2026
Hangzhou Heda Xinyiyao
Note 2
5,371,750 (including
5,371,750 H Shares)
7.30% 3.79% June 29, 2026


--- page 9 ---
9
Name
Number of
shares held in the
Company subject to
lock-up undertakings
upon listing
% of total
issued H Shares
after the Global
Offering subject
to lock-up
undertakings
upon Listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings Note 1
Shenzhen Minhe
Investment Co., Ltd. ( ଉέ
ʮ̡ )
2,739,625 (including
2,739,625 H Shares)
3.72% 1.93% June 29, 2026
Hangzhou Haibang Boyuan
Venture Capital Partnership
(Limited Partnership) (ψ
ऎԞ௹๕௴ุҳ༟ΥྫΆ
ุ(Υྫ ))
2,283,000 (including
2,283,000 H Shares)
3.10% 1.61% June 29, 2026
Hainan Jingsheng Yiqi
Private Equity Investment
Fund Partnership (Limited
Partnership) (౻ସɓ
Υྫ
Άุ(Υྫ ))
1,369,750 (including
1,369,750 H Shares)
1.86% 0.97% June 29, 2026
Nanjing Outao Information
Technology Co., Ltd. (ԯ
ʮ̡ )
1,369,750 (including
1,369,750 H Shares)
1.86% 0.97% June 29, 2026
Total 29,475,125 40.04% 20.79%
Notes:
1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
2. The Company has applied for, and the Stock Exchange has granted a written consent under Paragraph 5(2) of
the Placing Guidelines in relation to allocation to Jingui Yueke, a close associate of an existing shareholder
and pre-IPO investor of the Company, Hangzhou Heda Xinyiyao. For details, please refer to the section headed
“Others/Additional Information ” in this announcement below.


--- page 10 ---
10
PLACEE CONCENTRATION ANALYSIS
Placees *
Number of
H Shares allotted
Allotment as %
of International
Offering
Allotment as %
of total
Offer Shares
Number of
Shares held
upon Listing
% of total issued
share capital upon
Listing
Top 1 3,346,300 39.84% 19.92% 3,346,300 2.36%
Top 5 7,437,700 88.54% 44.27% 7,437,700 5.25%
Top 10 8,389,500 99.88% 49.94% 8,389,500 5.92%
Top 25 8,391,000 99.89% 49.95% 8,391,000 5.92%
Notes
* Ranking of placees is based on the number of H Shares allotted to the placees.
H SHAREHOLDER CONCENTRATION ANALYSIS
H Shareholders*
Number of
H Shares allotted
Allotment as %
of International
Offering
Allotment as %
of total
Offer Shares
Number of
H Shares held
upon Listing
% of total issued
H Shares capital
upon Listing
Number of Shares
held upon Listing
Top 1 0 0.00% 0.00% 27,323,763 37.13% 95,524,875
Top 5 3,346,300 39.84% 19.92% 57,405,688 78.00% 125,606,800
Top 10 6,952,400 82.77% 41.38% 63,751,288 86.62% 131,952,400
Top 25 8,558,700** 101.89% 50.94% 65,357,588 88.80% 133,558,700
Notes
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
** Including H Shares allotted under the Hong Kong Public Offering and International Offering and among which,
169,400 H Shares were allotted under the Hong Kong Public Offering and 8,389,300 H Shares were allotted
under the International Offering.
For the purpose of the shareholder concentration analysis, all Shares owned by Hangzhou Heda Xinyiyao and Jingui
Yueke are aggregated.
SHAREHOLDER CONCENTRATION ANALYSIS
Shareholders *
Number of
H Shares allotted
Allotment as %
of International
Offering
Allotment as %
of total
Offer Shares
Number of
H Shares held
upon Listing
Number of
Shares held
upon Listing
% of total issued
share capital
upon Listing
Top 1 0 0.00% 0.00% 27,323,763 95,524,875 67.37%
Top 5 3,346,300 39.84% 19.92% 57,405,688 125,606,800 88.58%
Top 10 6,952,400 82.77% 41.38% 63,751,288 131,952,400 93.06%
Top 25 8,558,700** 101.89% 50.94% 65,357,588 133,558,700 94.19%


--- page 11 ---
11
Note
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
** Including H Shares allotted under the Hong Kong Public Offering and International Offering and amongst
which, 169,400 H Shares were allotted under the Hong Kong Public Offering and 8,389,300 H Shares were
allotted under the International Offering.
For the purpose of the shareholder concentration analysis, all Shares owned by Hangzhou Heda Xinyiyao and Jingui
Yueke are aggregated.
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, 70,338 valid applications
made by the public will be conditionally allocated on the basis set out below:
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED OF THE
TOTAL NO. OF
SHARES
APPLIED FOR
POOL A
100 24,499 12,250 out of 24,499 to receive 100 Shares 50.00%
200 5,895 3,006 out of 5,895 to receive 100 Shares 25.50%
300 5,426 2,784 out of 5,426 to receive 100 Shares 17.10%
400 2,251 1,156 out of 2,251 to receive 100 Shares 12.84%
500 2,807 1,443 out of 2,807 to receive 100 Shares 10.28%
600 1,423 732 out of 1,423 to receive 100 Shares 8.57%
700 929 479 out of 929 to receive 100 Shares 7.37%
800 908 469 out of 908 to receive 100 Shares 6.46%
900 452 234 out of 452 to receive 100 Shares 5.75%
1,000 5,390 2,796 out of 5,390 to receive 100 Shares 5.19%
1,500 2,057 1,070 out of 2,057 to receive 100 Shares 3.47%
2,000 2,054 1,073 out of 2,054 to receive 100 Shares 2.61%
2,500 799 419 out of 799 to receive 100 Shares 2.10%
3,000 1,628 859 out of 1,628 to receive 100 Shares 1.76%
3,500 1,026 545 out of 1,026 to receive 100 Shares 1.52%
4,000 798 427 out of 798 to receive 100 Shares 1.34%
4,500 442 238 out of 442 to receive 100 Shares 1.20%
5,000 1,468 798 out of 1,468 to receive 100 Shares 1.09%
6,000 816 448 out of 816 to receive 100 Shares 0.92%
7,000 732 410 out of 732 to receive 100 Shares 0.80%
8,000 614 354 out of 614 to receive 100 Shares 0.72%
9,000 342 200 out of 342 to receive 100 Shares 0.65%


--- page 12 ---
12
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED OF THE
TOTAL NO. OF
SHARES
APPLIED FOR
10,000 2,730 1,643 out of 2,730 to receive 100 Shares 0.60%
20,000 1,208 100 Shares 0.50%
30,000 725 100 Shares plus 276 out of 725 to receive
additional 100 Shares
0.46%
40,000 497 100 Shares plus 318 out of 497 to receive
additional 100 Shares
0.41%
50,000 453 200 Shares 0.40%
60,000 242 200 Shares plus 82 out of 242 to receive additional
100 Shares
0.39%
70,000 219 200 Shares plus 145 out of 219 to receive
additional 100 Shares
0.38%
80,000 190 300 Shares 0.38%
90,000 102 300 Shares plus 15 out of 102 to receive additional
100 Shares
0.35%
100,000 349 300 Shares plus 140 out of 349 to receive
additional 100 Shares
0.34%
150,000 202 500 Shares 0.33%
69,673 Total number of Pool A successful applicants:
38,020
POOL B
200,000 383 4,400 Shares 2.20%
250,000 39 5,300 Shares 2.12%
300,000 54 6,200 Shares 2.07%
350,000 40 7,100 Shares 2.03%
400,000 22 7,900 Shares 1.98%
450,000 15 8,600 Shares 1.91%
500,000 35 9,400 Shares 1.88%
600,000 24 11,200 Shares 1.87%
700,000 11 12,900 Shares 1.84%
840,000 42 15,400 Shares 1.83%
665 Total number of Pool B successful applicants: 665
As of the date of this announcement, the relevant subscription monies previously deposited in the
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
Investors should contact their relevant brokers for any inquiries.


--- page 13 ---
13
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
which consent has been obtained, the Company has complied with the Listing Rules and guidance
materials in relation to the placing, allotment and listing of the Company ’s H Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees
or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or
purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC
transaction levy, SFC transaction levy and trading fee payable.
OTHERS/ADDITIONAL INFORMATION
Allocation of Offer Shares to a close associate of an existing Shareholder as placee (with
prior written consent under Paragraph 5(2) of the Placing Guidelines)
Jingui Yueke is a close associate of an existing Shareholder of the Company, Hangzhou Heda
Xinyiyao.
As of the date of the Prospectus, Hangzhou Heda Xinyiyao held 5,371,750 Shares, representing
approximately 4.30% of the total number of issued Shares of the Company prior to the Global
Offering. Jingui Yueke has been placed 3,346,300 H Shares at the Offer Price as a placee,
representing approximately 19.92% of the total number of Offer Shares available under the
Global Offering and approximately 2.36% of the total issued Shares of the Company upon
completion of the Global Offering.
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a
consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate such
Offer Shares in the International Offering to Jingui Yueke. The allocation of Offer Shares to
Jingui Yueke is in compliance with all the conditions under the consent granted by the Stock
Exchange.
Reallocation
As the Hong Kong Public Offering has been over-subscribed by more than 100 times of the
number of the Offer Shares initially available for subscription under the Hong Kong Public
Offering, the reallocation procedure as disclosed in the paragraph headed “Structure of the
Global Offering – The Hong Kong Public Offering – Reallocation and Clawback ” in the
Prospectus has been applied.
The number of Offer Shares initially available under the Hong Kong Public Offering was
1,680,000 H Shares, representing approximately 10% of the total number of Offer Shares
initially available under the Global Offering. As a result of such reallocation, the final number
of Offer Shares under the Hong Kong Public Offering is adjusted to 8,400,000 H Shares,
representing approximately 50% of Offer Shares initially available under the Global Offering.


--- page 14 ---
14
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and
Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or
any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into
the United States (including its territories and possessions, any state of the United States and the
District of Columbia). This announcement does not, and is not intended to, constitute or form a
part of any offer to sell or solicitation to purchase or subscribe for any securities in the United
States. The Offer Shares have not been, and will not be, registered under the United States
Securities Act of 1933, as amended (the “U.S. Securities Act ”) or securities law of any state
or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise
transferred within the United States, except pursuant to an available exemption from, or in a
transaction not subject to, the registration requirements of the U.S. Securities Act. There will be
no public offer of the Offer Shares in the United States.
The Offer Shares are being offered and sold solely outside the United States in offshore
transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or
offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus.
Potential investors should read the Prospectus dated June 20, 2025 issued by Medtide Inc. for
detailed information about the Global Offering described below before deciding whether or not
to invest in the H Shares thereby being offered.
*  Potential investors of the Offer Shares should note that the Overall Coordinators (for
themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their
obligations under the Hong Kong Underwriting Agreement with immediate effect upon the
occurrence of any of the events set out in the section headed “Underwriting – Hong Kong
Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination ” in the
Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is
currently expected to be on Monday, June 30, 2025).
PUBLIC FLOAT
Immediately after the completion of the Global Offering, an aggregate of 37,143,250 H Shares,
representing approximately 26.19% of the issued share capital of the Company will be held in
public hands. Therefore, the number of H Shares held in public hands represents no less than 25%
of the total issued share capital of the Company, satisfying the minimum percentage requirement in
compliance with Rule 8.08 (1) of the Listing Rules.
The Directors confirm that, immediately following completion of the Global Offering: (i) no placee
will, individually, be placed more than 10% of the enlarged issued share capital of the Company
immediately after the Global Offering; (ii) there will not be any new substantial Shareholder
immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more
than 50% of the H Shares in public hands at the time of Listing in compliance with Rules 8.08(3)
and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of Listing
in compliance with Rule 8.08(2) of the Listing Rules.


--- page 15 ---
15
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, June
30, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the
right of termination described in the section headed “Underwriting – Hong Kong Underwriting
Arrangements – Hong Kong Public Offering – Grounds for Termination ” in the Prospectus has
not been exercised. Investors who trade the H Shares on the basis of publicly available allocation
details prior to the receipt of H Share certificates or prior to the H Share certificates becoming
valid evidence of title do so entirely at their own risk.
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, June
30, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange
will commence at 9:00 a.m. on Monday, June 30, 2025 (Hong Kong time). The H Shares will be
traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 3880.
By order of the Board
Medtide Inc.
इᅃᔼᖹ (एϪ)ʮ̡
Dr. Xu Qi
Chairwoman, Executive Director and
Chief Executive Officer
Hong Kong, June 27, 2025
As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Xu
Qi (Chairwoman of the board), Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao and Ms. Li Lingmei
as executive directors; (ii) Mr. Wu Yihui as non-executive director; and (iii) Dr. Yu Cheung Hoi,
Dr. Zhu Xun and Mr. Xia Xinsheng as proposed independent non-executive Directors, effective
upon Listing.
